GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: March 15, 2012
Application Number:
20120064129
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE
Granted: March 15, 2012
Application Number:
20120064168
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE
Granted: February 2, 2012
Application Number:
20120027823
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT
Granted: December 8, 2011
Application Number:
20110301129
Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a…
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: October 20, 2011
Application Number:
20110256223
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
SHELL AND CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE
Granted: September 29, 2011
Application Number:
20110236485
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
METHODS OF TREATING NON-NOCICEPTIVE PAIN STATES WITH GASTRIC RETENTIVE GABAPENTIN
Granted: September 8, 2011
Application Number:
20110218246
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE
Granted: May 5, 2011
Application Number:
20110104272
Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE
Granted: May 5, 2011
Application Number:
20110104273
Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN
Granted: March 3, 2011
Application Number:
20110052685
Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF LEVOSULPIRIDE
Granted: March 3, 2011
Application Number:
20110052700
Gastric retentive oral dosage forms which provide both immediate and extended release of levosulpiride are described which may allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
Granted: August 5, 2010
Application Number:
20100196474
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS
Granted: February 18, 2010
Application Number:
20100040689
The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
Granted: January 21, 2010
Application Number:
20100015222
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM
Granted: August 20, 2009
Application Number:
20090209645
Methods for treating vasomotor symptoms associated with menopause are described.
GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
Granted: July 9, 2009
Application Number:
20090176882
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
Pulsatile gastric retentive dosage forms
Granted: January 29, 2009
Application Number:
20090028941
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastro-esophageal reflux disease…
Gastric retentive gabapentin dosage forms and methods for using same
Granted: August 9, 2007
Application Number:
20070184104
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
Granted: July 20, 2006
Application Number:
20060159743
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
Dual drug dosage forms with improved separation of drugs
Granted: January 20, 2005
Application Number:
20050013863
Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any…
